Coloplast Group

Denmark · owned by Independent (Denmark) · coloplast.com · 20 vendors

Coloplast creates intimate healthcare solutions for people with ostomy, continence, wound care, and other medical needs. The company helps over 2 million people annually across 100+ countries with products including ostomy bags, catheters, wound dressings, and surgical implants.

Resilience scores

Technology vendors

Services catalogue

1 service in catalogue across 1 category; runs on 20 sub-vendors.

Insights

Last updated 2026-01-28 · revision 2

20 direct vendors, 286 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 6/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Coloplast appears to be in the midst of a digital transformation, with significant investment in modern, cloud-based platforms like Azure, SAP S/4HANA, and Salesforce. This indicates a strategic move away from legacy systems. However, as a large, established company in the highly regulated medical sector, it likely still operates significant on-premise infrastructure and legacy applications. The complexity of migrating validated systems under medical device regulations (e.g., FDA 21 CFR Part 11) introduces significant challenges and slows down the migration process. Therefore, they are considered moderately flexible with a mix of modern and legacy systems.

Financials

Three-year financials

Financial Resilience Score: 9/10

Coloplast's core products are essential for users with chronic medical conditions. This creates a highly stable and predictable demand, making the company exceptionally resilient to economic downturns. Customers cannot easily postpone or forgo purchasing these products. An EBIT margin consistently near 30% is best-in-class within the MedTech industry. This provides a substantial buffer to absorb cost inflation or fund strategic investments without compromising financial stability. Coloplast has historically maintained a strong balance sheet with a low net debt-to-EBITDA ratio. This conservative capital structure provides significant financial flexibility for M&A, R&D investment, and shareholder returns (dividends). The company holds #1 or #2 market share positions globally in its key business areas of Ostomy Care and Continence Care. This market dominance creates a significant competitive moat, reinforcing its pricing power and long-term stability. While heavily weighted towards Europe, the company has a strong and growing presence in North America and other developed markets, which mitigates risk from any single economy.

Key strengths: Non-Discretionary Product Portfolio, High and Stable Profitability, Strong Balance Sheet & Low Leverage, Market Leadership, Geographic Diversification

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report